Open Medicine (Sep 2022)

Lineage switch from lymphoma to myeloid neoplasms: First case series from a single institution

  • Yang Wenjuan,
  • Xie Shuangfeng,
  • Li Yiqing,
  • Wang Jieyu,
  • Xiao Jie,
  • Huang Kezhi,
  • Wang Xiuju,
  • Wu Yudan,
  • Ma Liping,
  • Nie Danian

DOI
https://doi.org/10.1515/med-2022-0521
Journal volume & issue
Vol. 17, no. 1
pp. 1466 – 1472

Abstract

Read online

Lymphoma relapse is very common in clinical work, but lineage switch at relapse is rare. Although some cases have reported acute lymphocytic leukemia (ALL) switch to acute myeloid leukemia (AML) or myeloid sarcoma upon relapse, phenotype switch seldom occurs in other types of lymphoma. Here we report six cases with lineage switch from lymphoma to myeloid neoplasms. In our cohort, three cases were mantle cell lymphoma (MCL), and the other three cases were T-cell lymphoblastic lymphoma (T-LBL), B-cell lymphoblastic lymphoma (B-LBL), and diffuse large B-cell lymphoma (DLBCL) at the initial diagnosis. When linage switch occurred, most cases were AML M5 phenotypes, and only one case was myelodysplastic syndrome (MDS) phenotype. 11q23/mixed-lineage leukemia (MLL) rearrangement was negative in all cases. Although intensive therapy and stem cell transplantation have been applied in most cases, the poor outcome cannot be reversed. Therefore, we found that lineage switch could occur not only from ALL to AML or vice versa, but also from MCL or DLBCL to AML. Moreover, the incidence of MLL rearrangement in lineage switch is lower in adult hematologic malignancies as compared with pediatric patients.

Keywords